Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Mar;8(Suppl 2):S87-S93.
doi: 10.21037/tcr.2018.08.21.

Anti-GD2 CAR T cells could prove transformative for H3-K27M+ diffuse midline gliomas

Koichi Furukawa  1 , Yuhsuke Ohmi  2 , Keiko Furukawa  1
Affiliations
Editorial

Anti-GD2 CAR T cells could prove transformative for H3-K27M+ diffuse midline gliomas

Koichi Furukawa et al. Transl Cancer Res. 2019 Mar.

Erratum in

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2018.08.21). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Synthetic pathway of glycosphingolipids. Main series of glycosphingolipids were indicated in italic. Main glycosyltransferases involved in the synthesis of individual structures were also indicated in italic. Deleted structures in the individual knockout of glycosyltransferases were shown by enclosing with squares. Representative mono- and disialyl gangliosides known to suppress or enhance malignant properties of cancer cells were marked blue or reddish backgrounds, respectively.
Figure 2
Figure 2
Anti-GD2 CAR T cells are promising approach to treat DIPG. Anti-GD2 CAR T cells could infiltrate into glioma tissues, and eliminate almost completely GD2-expressing cells after systemic injection (A). In contrast, anti-GD2 mAbs are hard to access glioma cells by crossing the blood brain barrier (B). This may be also the case in anti-immune check-point antibodies. DIPG, diffuse intrinsic pontine glioma.
See this image and copyright information in PMC

Comment on

References

    1. Huse JT, Holland EC. Targeting brain cancer: advances in the moleculer pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 2010;10:319-31. 10.1038/nrc2818 - DOI - PubMed
    1. Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 2014;46:444-50. 10.1038/ng.2938 - DOI - PMC - PubMed
    1. Mount CW, Majzner RG, Sundaresh S, et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nat Med 2018;24:572-9. 10.1038/s41591-018-0006-x - DOI - PMC - PubMed
    1. Suzuki K. The pattern of mammalian brain gangliosides. II. Evaluation of the extraction procedures, postmortem changes and the effect of formalin preservation. J Neurochem 1965;12:629-38. 10.1111/j.1471-4159.1965.tb04256.x - DOI - PubMed
    1. Ahmed M, Cheung NK. Engineering anti-GD2 monoclonal antibodies for cancer immuneotherapy. FEBS Lett 2014;588:288-97. 10.1016/j.febslet.2013.11.030 - DOI - PubMed